CORONAVIRUS/Taiwan-developed COVID drug trial shows positive clinical results

01/05/2022 09:09 PM
To activate the text-to-speech service, please first agree to the privacy policy below.

Taipei, Jan. 5 (CNA) Taiwanese biopharmaceutical company Golden Biotechnology Corp. on Wednesday released positive interim unblinded data from the Phase 2 clinical trial of its oral investigational new drug for COVID-19 Antroquinonol, and announced it plans to apply for Emergency Use Authorization (EUA) in the United States in April.

(Full text of the story is now in CNA English news archive. To view the full story, you will need to be a subscribed member of the CNA archive. To subscribe, please read here.)

View All
We value your privacy.
Focus Taiwan (CNA) uses tracking technologies to provide better reading experiences, but it also respects readers' privacy. Click here to find out more about Focus Taiwan's privacy policy. When you close this window, it means you agree with this policy.